Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US FDA Advertising Citations Remain Rare In 2018

Executive Summary

With only seven letters last year, Office of Prescription Drug Promotion appears to be continuing its enforcement retrenchment as agency reconsiders its approach to Rx communications.


Related Content

Trump Administration's Rx Drug Price Disclosure Reg Seen As Unworkable
Advertising Enforcement: US FDA Content To Let Competitors 'Duke It Out,' Woodcock Says
PhRMA Criticizes 'Exponential Pace' Of FDA Rx Drug Advertising Studies
Rx Drug Ads: New US FDA Studies Target Accelerated Approval Information
US FDA Calls Foul On CSL Behring Hemophilia Drug Promo
Rx Promotion Citations By US FDA Plummet; UCLA Webpage Elicits Final Letter Of 2017
Rx Ad Studies Target Risk Info Location, Efficacy Framing, Oncology Products
First Amendment Does Not Block Off-Label Enforcement Actions, FDA Reiterates
DDMAC's Latest Exhibit Hall Citation Is Vectibix; Firms Try Multiple Ways To Avoid FDA At Trade Shows
Four Ways To Draw DDMAC's Ire: In Print, On A Dosing Card, In A Script, And In Person


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts